Raymond James downgrades Compass Therapeutics stock rating on trial results

Raymond James downgraded Compass Therapeutics to Market Perform from Outperform after mixed Phase 3 COMPANION-002 results for tovecimig. Progression-free survival was statistically significant with a hazard ratio of 0.44, but the study missed overall survival with a hazard ratio above 1, prompting reduced approval confidence and lower projected revenues. The stock has already fallen 66% in a week to $1.79 as analysts reassess the drug’s commercialization outlook.

Analysis

CMPX is now in the classic post-binary-event digestion phase where the market usually overweights the headline miss and underweights what still has option value. The key issue is not just approval probability; it is that a “PFS-positive / OS-negative” profile materially weakens payer enthusiasm and pushes FDA scrutiny onto clinical relevance, which can compress the implied commercial peak even if the asset remains viable. That makes the next leg less about science and more about whether management can reframe the dataset into a path that preserves partnering leverage.

Second-order, this is a read-through for late-stage micro-cap oncology names where single-asset risk is priced as if statistical significance alone can carry valuation. If regulators or KOLs view the endpoint mix as insufficiently persuasive, capital markets will likely punish similar programs with narrower tolerances for noise in survival curves and delayed data releases. The slower accrual comment also matters: programs with operational slippage now face a higher discount rate because investors assume hidden fragility, not just trial logistics.

The contrarian angle is that the stock may be entering “too hated to short” territory after a 66% drawdown, especially if the company has enough runway to bridge to FDA feedback and pipeline updates in 2026. But any reflex rally is likely to fade unless there is concrete evidence of regulatory alignment or another asset with cleaner translational economics. The market is probably still too optimistic on a quick salvage rerating; in this setup, time is the enemy because every month without a clear approval path erodes the buyout/partnering narrative.

Key Decisions for Investors

• Avoid initiating fresh long exposure in CMPX for the next 1-2 months; the setup is still an information overhang trade, not a fundamentals inflection.
• For existing longs, trim into any 10-15% relief rally and keep only a residual position for FDA-feedback optionality; downside can reaccelerate if the company signals a narrower label or additional delay.
• Consider a tactical short against a basket of other speculative oncology names with upcoming readouts if liquidity allows; CMPX is a template for how markets will reprice mixed efficacy/survival data.
• If you want exposure, structure it as a call-spread on a positive regulatory clarification over the next 3-6 months rather than common stock; the asymmetry is better defined than outright equity.